Kezar Life Sciences

About Kezar Life Sciences

Kezar Life Sciences, established in 2015, is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for immune-mediated diseases and oncology. The company was co-founded by Christopher Kirk, Ph.D., and John Fowler, who have known each other since childhood. Dr. Kirk, an immunologist and tumor biologist, serves as the CEO and previously held key roles at Onyx Pharmaceuticals, contributing to the development of the proteasome inhibitor carfilzomib (Kyprolis). John Fowler brought diverse executive leadership experience to his role as the founding CEO, having previously led a patient advocacy firm and a specialty logistics company after starting his career in government and management consulting. This unique blend of deep scientific expertise and broad business acumen has shaped the company's trajectory.

Headquartered in South San Francisco, California, Kezar operates a research-driven business model. Its financial strategy relies on capital raised through public offerings and potential future revenue from partnerships, collaborations, and licensing agreements with other pharmaceutical companies. The company went public in June 2018, raising approximately $75 million through its initial public offering to advance its clinical programs.

Kezar's therapeutic pipeline targets master regulators of cellular function. Its lead product candidate for autoimmune diseases is zetomipzomib (KZR-616), a first-in-class selective immunoproteasome inhibitor. The immunoproteasome is highly expressed in immune cells, and by inhibiting it, zetomipzomib can broadly modulate multiple pathways involved in the immune system's dysregulation without widespread immune suppression. This mechanism gives it potential as a treatment for a wide array of autoimmune conditions, including lupus nephritis and autoimmune hepatitis, where it is being evaluated in mid-stage clinical trials. The aim is for zetomipzomib to serve as a steroid-sparing agent, addressing a significant need in autoimmune disease management.

In oncology, Kezar is developing KZR-261, an inhibitor of the Sec61 translocon, a cellular pathway responsible for protein secretion. This program targets the disruption of processes critical for tumor growth and is being evaluated in a Phase 1 clinical trial for solid tumors. In late 2023, the company underwent a strategic restructuring to prioritize its clinical-stage assets, pausing discovery-stage research to extend its financial runway and focus on achieving key clinical data readouts for both zetomipzomib and KZR-261.